Thread by @SarahKarlin

Here's a run down of some of our stories on $BIIB's Aduhelm approval for Alzheimer's (and then I'll try to stop tweeting about this for a bit :)

@brendasandburg on the unexpectedly BROAD label that doesn't align with trial population.

pink.pharmaintelligence.informa.com/PS144439/Bioge…

@brendasandburg .@PinkSheetSutter looks at the implications of FDA approving the drug via the accelerated approval pathway, including what it means for future FDA decisions.

pink.pharmaintelligence.informa.com/PS144437/Aduca…

@brendasandburg @PinkSheetSutter .@ScripMandy goes into more detail on the other drugs in Alzheimer's space that could benefit from the decision to used amyloid-beta as a surrogate.

scrip.pharmaintelligence.informa.com/SC144494/Aduhe…

@brendasandburg @PinkSheetSutter @ScripMandy .@dgingery has some interesting info on key meetings with FDA that took place after the advisory committee that may have influenced the decision -- including one with patient advocates. pink.pharmaintelligence.informa.com/PS144438/Patie…